Zai Lab (NASDAQ:ZLAB) Shares Climb 13% Following Better-Than-Expected Earnings

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) were up 13% on Friday after the company announced better than expected quarterly earnings. The company traded as high as $25.40 and last traded at $25.5380. Approximately 826,219 shares were traded during trading, a decline of 7% from the average daily volume of 884,654 shares. The stock had previously closed at $22.60.

The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. The company had revenue of $108.21 million during the quarter, compared to analysts’ expectations of $107.90 million. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%.

Zai Lab News Roundup

Here are the key news stories impacting Zai Lab this week:

• Positive Sentiment: Zai Lab reported a loss of $0.41 per ADS, beating the consensus estimate of a $0.59 loss. Revenue of $108.21 million also slightly topped the $107.90 million analyst estimate. The earnings beat likely supported investor sentiment. Earnings flash
• Positive Sentiment: The company said it is advancing internally developed medicines, with coverage highlighting the pipeline’s potential to reach a first U.S. drug filing. Progress toward that milestone could offer a longer-term growth catalyst. Zai Lab Q3 2026: Loss Narrows 27%, Pipeline Eyes First US Drug Filing
• Negative Sentiment: Despite the estimate beat, Zai Lab remains loss-making, and reports characterized quarterly revenue as declining. Those trends temper the positive earnings surprise. Zai Lab Q3 Loss Widens, Revenue Declines

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Citigroup lifted their price target on Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wall Street Zen upgraded Zai Lab from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a research report on Tuesday, October 27th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $37.25.

Insiders Place Their Bets

In other news, Director William Lis sold 8,506 shares of Zai Lab stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $25.00, for a total value of $212,650.00. Following the transaction, the director owned 41,931 shares in the company, valued at approximately $1,048,275. The trade was a 16.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 9,385 shares of company stock worth $235,145 in the last quarter. Company insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On Zai Lab

Several large investors have recently bought and sold shares of ZLAB. Nan Fung Trinity HK Ltd. boosted its position in Zai Lab by 106.9% in the third quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company’s stock worth $7,743,000 after purchasing an additional 151,883 shares during the last quarter. Alps Advisors Inc. increased its stake in shares of Zai Lab by 34.9% in the third quarter. Alps Advisors Inc. now owns 148,993 shares of the company’s stock worth $3,924,000 after purchasing an additional 38,562 shares in the last quarter. Seven Fleet Capital Management LP lifted its stake in shares of Zai Lab by 74.7% during the 2nd quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock valued at $2,584,000 after buying an additional 58,158 shares in the last quarter. Headlands Technologies LLC lifted its position in shares of Zai Lab by 142.0% in the second quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock valued at $1,292,000 after acquiring an additional 39,901 shares in the last quarter. Finally, WealthPlan Investment Management LLC purchased a new stake in shares of Zai Lab during the third quarter worth about $969,000. 41.65% of the stock is currently owned by institutional investors.

Zai Lab Stock Performance

The stock has a fifty day moving average of $24.64 and a 200 day moving average of $21.02. The company has a market capitalization of $2.92 billion, a PE ratio of -15.00 and a beta of 0.77.

Zai Lab Company Profile

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.